Clinical trial · Observational
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will determine if patient-derived tumor xenograft (PDX) mouse models can serve as a reliable model for treatment response for individual patients with triple negative breast cancer. The collection of patient tumor tissue will also provide insight into the mechanisms of therapeutic resistance for those individuals. Ultimately, this study will enhance our understanding of the genomic basis for treatment response for triple negative cancer on an individual basis, while having the potential to suggest new therapeutic options for high-risk triple negative breast cancer patients with residual disease post neoadjuvant.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Triple Negative Breast Cancers
- description
- All women eligible for this protocol will fall into this group. These women will have histologically confirmed triple negative breast cancer and be eligible for neoadjuvant chemotherapy or have evidence of metastatic disease.
- interventionNames
- Other: Chemotherapy
Primary outcomes (1)
- measure
- Patient Tumor Response
- timeFrame
- Day 1
- description
- Tumor response in patients will be categorized as: Progressive Disease, Static Response, Partial Response, Complete Response
Secondary outcomes (1)
- measure
- Model Tumor Response
- timeFrame
- Day 1
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * a histological diagnosis of invasive triple negative breast cancer determined by standard immunohistochemical analysis. * must be candidates for neoadjuvant chemotherapy according to standard of care guidelines or have evidence of metastatic disease. * must agree to a biopsy for research purposes at time of diagnosis and to undergo surgery at the hospitals of the Mount Sinai Health System. Patients with the following MAY be eligible: \- a histological diagnosis of ER and/or PR positive breast cancer with an overall receptor expression ≤ 30% breast cancer determined by standard immunohistochemical analysis Exclusion Criteria: * concurrent disease or condition that would make the patient inappropriate for study participation, * any serious medical or psychiatric disorder that would interfere with the subject's safety, or inability to provide informed consent. * vulnerable populations will not be included.
References
Publications (0)
Data not yet available